Hari L. Ratan

Nottingham University Hospitals NHS Trust — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

11h-index372citations52works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Histone Deacetylase Inhibitors Research(21), Cancer Genomics and Diagnostics(15), Epigenetics and DNA Methylation(14), Radiomics and Machine Learning in Medical Imaging(7), Lung Cancer Treatments and Mutations(6)

Publications52 total

Missed opportunities in hypercalcaemic stone formers: detecting primary hyperparathyroidism
Endocrine Abstracts·2026
Are we far from getting it right? Contemporary practices in culturing urine pre‐ureteroscopy
British Journal of Urology·2026Open Access
Recommendation on the use of protective eyewear in endourological laser procedures
British Journal of Urology·2025· 1 citedOpen Access
Epitranscriptomic mechanisms of androgen signalling and prostate cancer
Neoplasia·2024· 4 citedOpen Access
Ureteroscopic treatment of urolithiasis: How do we measure and optimise outcomes?
Journal of Clinical Urology·2024· 1 cited
Modulation of the pre-metastatic bone niche: molecular changes mediated by bone-homing prostate cancer extracellular vesicles
Frontiers in Cell and Developmental Biology·2024· 2 citedOpen Access
Supplementary Figure 3 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure 1 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure 5 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Methods from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure 4 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Methods from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure 4 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure 1 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure 6 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure 5 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure Legends from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Table 1 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure Legends from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
Supplementary Figure 3 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Anna M. Grabowska(23), Philip A. Clarke(22), David Onion(21), Richard H. Argent(21), Alexander M. Reece-Smith(21), Madeleine L. Craze(21), Robert G. Pineda(21), Simon L. Parsons(21), Dileep N. Lobo(21), John P. Duffy(21), John C. Atherton(21), Andrew J. McKenzie(21), Rajendra Kumari(21), Brett M. Hall(21), Peter King(20), Daron Smith(3), Sharon Scriven(3), William J.F. Green(2), Richard Parkinson(2), Graham Johnson(2)